Traws Pharma Statistics
Total Valuation
Traws Pharma has a market cap or net worth of $4.38 million. The enterprise value is -$636,041.
| Market Cap | 4.38M |
| Enterprise Value | -636,041 |
Important Dates
The next estimated earnings date is Tuesday, November 24, 2026, before market open.
| Earnings Date | Nov 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Traws Pharma has 15.37 million shares outstanding. The number of shares has increased by 138.41% in one year.
| Current Share Class | 15.37M |
| Shares Outstanding | 15.37M |
| Shares Change (YoY) | +138.41% |
| Shares Change (QoQ) | +49.09% |
| Owned by Insiders (%) | 6.51% |
| Owned by Institutions (%) | 27.47% |
| Float | 11.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.26 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.93, with zero debt.
| Current Ratio | 0.93 |
| Quick Ratio | 0.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -433.36% and return on invested capital (ROIC) is -270.57%.
| Return on Equity (ROE) | -433.36% |
| Return on Assets (ROA) | -99.40% |
| Return on Invested Capital (ROIC) | -270.57% |
| Return on Capital Employed (ROCE) | -1,241.73% |
| Weighted Average Cost of Capital (WACC) | 13.39% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.35M |
| Employee Count | 7 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.13% in the last 52 weeks. The beta is 1.66, so Traws Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.66 |
| 52-Week Price Change | -84.13% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 42.91 |
| Average Volume (20 Days) | 165,424 |
Short Selling Information
The latest short interest is 685,721, so 4.46% of the outstanding shares have been sold short.
| Short Interest | 685,721 |
| Short Previous Month | 690,685 |
| Short % of Shares Out | 4.46% |
| Short % of Float | 5.82% |
| Short Ratio (days to cover) | 0.48 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -21.54M |
| Pretax Income | -21.57M |
| Net Income | -16.44M |
| EBITDA | -21.40M |
| EBIT | -21.54M |
| Earnings Per Share (EPS) | -$1.47 |
Balance Sheet
The company has $5.02 million in cash and no debt, with a net cash position of $5.02 million or $0.33 per share.
| Cash & Cash Equivalents | 5.02M |
| Total Debt | n/a |
| Net Cash | 5.02M |
| Net Cash Per Share | $0.33 |
| Equity (Book Value) | 1.69M |
| Book Value Per Share | 0.11 |
| Working Capital | -712,000 |
Cash Flow
| Operating Cash Flow | -16.85M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 147,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -16.85M |
| FCF Per Share | -$1.10 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Traws Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -138.41% |
| Shareholder Yield | -138.41% |
| Earnings Yield | -516.94% |
| FCF Yield | -438.54% |
Analyst Forecast
The average price target for Traws Pharma is $1.00, which is 250.88% higher than the current price. The consensus rating is "Hold".
| Price Target | $1.00 |
| Price Target Difference | 250.88% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 23, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Sep 23, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
Traws Pharma has an Altman Z-Score of -84.72. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -84.72 |
| Piotroski F-Score | n/a |